Making Strides in the Treatment of B-Cell Malignancies - priME Oncology
Expert Perspectives
Expert Perspectives

Making Strides in the Treatment of B-Cell Malignancies

A Case-Based Educational Activity

Not a member of My prIME? Join now for instant access.

Gain thought leader insights on the options for the treatment of B-cell malignancies and review slides from prIME Oncology’s official Friday Satellite Symposium, preceding the 60th ASH Annual Meeting and Exposition in San Diego, California. Stay updated on the treatment of B-cell malignancies, including CLL, indolent non-Hodgkin lymphoma, aggressive lymphoma, mantle cell lymphoma, and more!

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.0 AMA PRA Category 1 Credit™

Release Date

Release Date

Dec 12, 2018

Expiration Date

Dec 12, 2019

  • Jacqueline Barrientos, MD, MSZucker School of Medicine at Hofstra/Northwell
    Lake Success, New York, United States
  • Richard I. Fisher, MDFox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • Simon Rule, MPhil, FRCP, FRCPA, FRCPathUniversity of Plymouth
    Plymouth, United Kingdom
  • John Seymour, MBBS, PhD, FRACPPeter MacCallum Cancer Centre
    Melbourne, Victoria, Australia
  • Nina Wagner-Johnston, MDJohns Hopkins Medicine
    Baltimore, Maryland, United States

A look at the hurdles associated with B-cell malignancies
Richard I. Fisher, MD

MCL: Going the distance with emerging treatment
Simon Rule, MD

Treatment of CLL: It’s a marathon, not a sprint
Jacqueline Barrientos, MD, MS

Keeping pace with treatment advances for FL
Nina Wagner-Johnston, MD

DLBCL: Mapping out a course for individualized treatment
John Seymour, MBBS, PhD, FRACP

This educational program is designed for hematologists, medical oncologists, and other healthcare professionals involved in the treatment of B-cell malignancies.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the underlying biology of B-cell malignancies and emerging therapeutic targets
  • Analyze recent clinical trial data supporting the efficacy and safety of current and emerging therapies for the treatment of patients with B-cell malignancies
  • Employ best practices in treatment selection and sequencing based on patient and disease-related factors
  • Identify optimal strategies for addressing treatment-related adverse events and improving patient safety and quality of life

This educational activity is supported by grants from AbbVie Inc.; Celgene Corporation; and Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditPhysicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. Your participation will be recorded in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Barrientos has disclosed being an independent contractor for AbbVie, Gilead, and Pharmacyclics. She also disclosed membership on an advisory committee or review panel for AbbVie, Gilead, Janssen, and Pharmacyclics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Fisher has disclosed that he has received consulting fees from Adaptive Biotechnologies, AstraZeneca, Bayer, Celgene, Genentech, Ion Solutions, and Sandoz. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Prof Rule has disclosed that he has received consulting fees from AstraZeneca, Janssen, Kite, and Karyopharm. He has also disclosed membership on an advisory committee or review panel for Pharmacyclics and Roche. He has disclosed that he has received honoraria for promotional speaker’s bureaus as well as speaking and teaching for Janssen and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Seymour has disclosed that he has received consulting fees from AbbVie, Celgene, Genentech, Janssen, Roche, and Takeda. He has received honoraria for promotional speaker’s bureaus from AbbVie, Celgene, and Roche. He disclosed as an independent contractor for AbbVie, Celgene, Janssen, and Roche.  He disclosed membership on an advisory committee or review panel for AbbVie, Celgene, Genentech, Janssen, Roche, and Takeda. He also disclosed speaking and teaching for AbbVie, Celgene, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wagner-Johnston has disclosed membership on an advisory committee or review panel for ACD Therapeutics and Janssen Pharmaceuticals. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.